Compare Incyte Corporation (INCY) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while JPMorgan Diversified Return International Eqty ETF trades at $73.03 (market cap $378.77M). The key difference: Incyte Corporation is far larger — about 60.3× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is more actively traded (13,861 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| INCY | JPIN | |
|---|---|---|
Market Cap | $22.85B | $378.77M |
Volume | 1,927,029 | 13,861 |
Sector | Health | — |
52-Week High | $129.93 | $77.80 |
52-Week Low | $83.80 | $64.96 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
JPIN trades at $72.875, down 0.09% with bearish technical signals dominating. The ETF shows oversold conditions with RSI readings below 25, while moving averages and oscillators indicate strong selling pressure. Recent analysis highlights JPIN's focus on international value stocks through a smart beta approach.
The ETF faces significant technical headwinds despite oversold conditions. Investors should weigh the bearish momentum against potential value opportunities in international markets, with the upcoming dividend payment in September 2026 providing income consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
